Taking part in the 9th Annual Kidney Health Advocacy Day, advocates from the American Association of Kidney Patients (AAKP) and ASN are urging their congressional delegations to increase funding for kidney research at the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to drive new breakthroughs for kidney patients and study the impact of COVID-19 on kidney health and people with kidney diseases.
Advocates from the American Association of Kidney Patients (AAKP) and ASN are calling on Congress to include funding for KidneyX in its annual government funding legislation and advance innovative technologies for kidney patients, such as a wearable or implantable artificial kidney.
Participating clinicians should begin the application process now.
The Centers for Medicare and Medicaid Services (CMS) has announced that it is accepting the impact of COVID-19 as a condition for applying for an Extreme and Uncontrollable Circumstances exemption in the Merit-based Incentive Payment System (MIPS).
For the 2020 performance year (PY), Medicare will be using its Extreme and Uncontrollable Circumstances policy to allow clinicians, groups, and virtual groups to submit an application requesting reweighting of one or more MIPS performance categories due to the current COVID-19 public health emergency. To provide additional support to clinicians, the agency is extending the extreme and uncontrollable circumstances application deadline for PY 2020 to Monday, February 1, 2021 at 8 p.m. ET.
Join ASN for New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes, a videoconference scheduled for Thursday, December 10, from 4:00 – 5:30 PM EST.
International clinical experts will review the latest guidelines for both kidney disease and cardiovascular disease, and discuss the most recent clinical trials and promising therapies, including the groundbreaking use of SGLT2 inhibitors to reduce morbidity and mortality. These are among the first new therapies demonstrated to help prevent the development of heart disease and reduce progression of kidney disease in people with T2DM.
The United States Renal Data System released its 2020 Annual Data Report, featuring the latest data accumulated through 2018. This report, funded by the National Institute of Diabetes and Digestive Kidney Diseases, provides an overview of the impact of kidney disease on the US population. The annual report developed by the USRDS serves as an invaluable resource for ASN and the kidney community in determining policy priorities and advocacy efforts. In addition to familiar findings health outcomes and health care spending related to kidney disease and kidney failure, the 2020 Annual Data Report reviews the impact of COVID-19 on kidney patients.
Consumer Reports (CR) recently published an article, “Medical Algorithms Have a Race Problem,” which recognized the potential impact ASN and the National Kidney Foundation (NKF) could have through their joint task force to reassess the inclusion of race in diagnosing kidney disease.
The American Society of Nephrology (ASN) is troubled by the Trump Administration’s decision to require submission of hospital data on COVID-19 patients directly to the Department of Health and Human Services (HHS) instead of the Centers for Disease Control and Prevention (CDC). This decision raises serious questions about the transparency and credibility of the data as well as concerns that the move will prevent researchers, public health officials, and other stakeholders from accessing the data to make projections and crucial decisions.
As the threat of COVID-19 was emerging in the United States, ASN and the broader kidney community participated in an effort organized by the Department of Health and Human Services (HHS) to develop policy recommendations that address the effects of COVID-19 on kidney patients and kidney care professionals.
The workgroups discussed and prioritized nearly 300 COVID-19-related kidney policy recommendations across seven key issue areas. HHS has already instituted many of the recommendations ASN and other stakeholders in the community made, and the society continues to work closely with the community to advocate for the policy recommendations to improve the care of kidney patients and protect the kidney care professionals that care for them.
Clinical trials often exclude people with kidney diseases. This means that 37 million people in the United States are rarely represented in the kind of research that advances change in treatment and care. The challenges that result from such exclusion are highlighted by the current COVID-19 crisis.